References
- Gwee K-A, Ghoshal UC, Chen M Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology, and management. J Gastroenterol Hepatol [Internet]. 2018 Jan 1;33(1):99–110. [cited 2018 Mar 16].
- Whelan K, Martin LD, Staudacher HM, et al. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet [Internet]. 2018 Apr 1;31(2):239–255. [cited 2018 Mar 16].
- Whitehead WE, Palsson OS, Simrén M Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol [Internet]. 2017 Apr 3;11(4):281–283. [cited 2018 Mar 16].
- Simren M, Palsson OS, Whitehead WE. Update on rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep [Internet]. 2017 Apr;19(4):15. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28374308
- Cong X, Ramesh D, Perry M, et al. Pain self-management plus nurse-led support in young adults with irritable bowel syndrome: study protocol for a pilot randomized control trial. Res Nurs Health [Internet]. 2018 Feb 1;[cited 2018 Mar 16]. DOI:10.1002/nur.21862
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol [Internet]. 2016 Oct 1;1(2):133–146. [cited 2018 Mar 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28404070
- Beckers AB, Weerts ZZRM, Helyes Z, et al. Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2017 Nov 1;46(10):938–952. [cited 2018 Mar 16].
- Sayuk GS, Gyawali CP. Irritable bowel syndrome: modern concepts and management options. Am J Med [Internet]. 2015 Aug;128(8):817–827.[cited 2018 Apr 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25731138
- Allen AP, Dinan TG, Clarke G, et al. A psychology of the human brain-gut-microbiome axis. Soc Personal Psychol Compass [Internet]. 2017 Apr;11(4):e12309. [cited 2018 May 21].
- Theodorou V, Ait Belgnaoui A, Agostini S, et al. Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes [Internet]. 2014;5(3):430–436. [cited 2018 Apr 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25184834
- Heitkemper M, Cain KC, Shulman R, et al. Subtypes of irritable bowel syndrome based on abdominal pain/discomfort severity and bowel pattern. Dig Dis Sci [Internet]. 2011 Jul;56(7):2050–2058. [cited 2018 Apr 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290181
- Hughes PA, Moretta M, Lim A, et al. Immune derived opioidergic inhibition of viscerosensory afferents is decreased in irritable bowel syndrome patients. 2014 Nov. 42:191–203. [cited 2018 May 21]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0889159114003912
- Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: regulation by the microbiome. Neurobiol Stress [Internet]. 2017 Dec;7:124–136. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29276734
- Gupta A, Kilpatrick L, Labus J, et al. Early adverse life events and resting state neural networks in patients with chronic abdominal pain. Psychosom Med [Internet]. 2014;76(6):404–412. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25003944
- Evangelista S. Novel therapeutics in the field of capsaicin and pain. Expert Rev Clin Pharmacol [Internet]. 2015 Jul 4;8(4):373–375. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25959004
- Saito YA, Strege PR, Tester DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Liver Physiol [Internet]. 2009 Feb;296(2):G211–G8. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19056759
- Zar S, Mincher L, Benson MJ, et al. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol [Internet]. 2005 Jan 8;40(7):800–807. [cited 2018 Apr 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16109655
- Gearry R, Skidmore P, O’Brien L, et al. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol [Internet]. 2016 Jun;9:131. [cited 2018 May 21]. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/27382323
- Bai T, Xia J, Jiang Y, et al. Comparison of the rome IV and rome III criteria for IBS diagnosis: a cross-sectional survey. J Gastroenterol Hepatol [Internet]. 2017 May;32(5):1018–1025. [cited 2018 Jun 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27862281
- Allen AP, Clarke G, Cryan JF, et al. Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms. Curr Med Res Opin [Internet]. 2017 Jul 3;33(7):1349–1351. [cited 2018 Mar 16]. Available from: https://www.tandfonline.com/doi/full/10.1080/03007995.2017.1322571
- Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am [Internet]. 2017 Mar;46(1):77–89. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28164854
- Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology [Internet]. 2009 Oct;137(4):1425–1434. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19596012
- Talley NJ, Fodor AA. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? Gastroenterology [Internet]. 2011 Nov;141(5):1555–1559. [cited 2018 May 21]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508511012546
- Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology [Internet]. 1996 Dec;111(6):1683–1699. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8942751
- Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol [Internet]. 2011 Jul 22;106(7):1290–1298. [cited 2018 May 21]. Available from: http://www.nature.com/articles/ajg201186
- Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol [Internet]. 2015;28(2):203–209. [cited 2018 May 21]. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/25830558
- Kunze WA, Mao Y-K, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med [Internet]. 2009 Aug 2;13(8b):2261–2270. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19210574
- Sobko T, Huang L, Midtvedt T, et al. Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radic Biol Med [Internet]. 2006 Sep 15;41(6):985–991. [cited 2018 May 21]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0891584906004229
- Undseth R, Jakobsdottir G, Nyman M, et al. Low serum levels of short-chain fatty acids after lactulose ingestion may indicate impaired colonic fermentation in patients with irritable bowel syndrome. Clin Exp Gastroenterol [Internet]. 2015 Nov;8:303–308. [cited 2018 May 21]. Available from: https://www.dovepress.com/low-serum-levels-of-short-chain-fatty-acids-after-lactulose-ingestion–peer-reviewed-article-CEG
- Trinkley KE, Nahata MC Treatment of irritable bowel syndrome. J Clin Pharm Ther [Internet]. 2011 Jun 1;36(3):275–282. [cited 2018 Mar 16].
- Camilleri M. Management of the irritable bowel syndrome. Gastroenterology [Internet]. 2001 Feb;120(3):652–668. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11179242
- Papatheodoridis GV. Management and current treatment of irritable bowel syndrome. Rev Ann Gastroenterol [Internet]. 2002;15(3):271–277. [cited 2018 May 21]. Available from: http://www.annalsgastro.gr/index.php/annalsgastro/article/view/162/139
- Chen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesthesiol Pain Med [Internet]. 2017 Jan 25;7(2):e42747. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28824858
- Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol [Internet]. 1996 Jan 8;31(5):463–468. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8734343
- Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol [Internet]. 2014 Aug 21;49(8):1193–1205. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24845149
- Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion [Internet]. 2008;77(3–4):225–235. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18667823
- Moore NA, Sargent BJ, Manning DD, et al. Partial agonism of 5-HT 3 receptors: a novel approach to the symptomatic treatment of IBS-D. ACS Chem Neurosci [Internet]. 2013 Jan 16;4(1):43–47. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23342199
- Sciarretta G, Fagioli G, Furno A, et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut [Internet]. 1987 Aug;28(8):970–975. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3666565
- Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut [Internet]. 2014 Oct;63(10):1617–1625. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24334242
- Goldberg PA, Kamm MA, Setti-Carraro P, et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (Ondansetron). Digestion [Internet]. 1996;57(6):478–483. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8913711
- Fukudo S, Hongo M, Kaneko H, et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil [Internet]. 2011 Jun;23(6):e544–e205. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21303430
- Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther [Internet]. 2008 Jan 30;27(8):685–696. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18248656
- Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther [Internet]. 2009 Feb 1;29(3):329–341. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19006537
- Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate. Gastroenterology [Internet]. 2013 Dec;145(6):1334–1346.e11. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23958540
- Rao S, Weber HC. New treatment targets for the management of irritable bowel syndrome. Curr Opin Endocrinol Diabetes Obes [Internet]. 2014 Feb 21;(1):9–14. [cited 2018 May]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24300740
- Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol [Internet]. 2012 Nov 18;107(11):1714–1724. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22986440
- Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol [Internet]. 2012 Nov 18;107(11):1702–1712. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22986437
- Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2004 Dec;20(11–12):1253–1269. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15606387
- Clavé P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2011 Aug;34(4):432–442. [cited 2018 May 21].
- Boeckxstaens G, Corazziari ES, Mearin F, et al. IBS and the role of otilonium bromide. Int J Colorectal Dis [Internet]. 2013 Mar 22;28(3):295–304. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23178991
- Whitehead WE, Levy RL, Von Korff M, et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2004 Dec;20(11–12):1305–1315. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15606392
- Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2008 Apr;27(8):678–684. [cited 2018 May 21].
- Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther [Internet]. 2005 Sep 1;22(5):381–385. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16128675
- Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut [Internet]. 2005 Sep 27;55(8):1095–1103. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16401691
- Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol [Internet]. 2004 May;99(5):914–920. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15128360
- Quartero AO, Meiniche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. In: Quartero AO, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2005. CD003460. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15846668
- O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology [Internet]. 2005 Mar;128(3):541–551. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15765388
- Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut [Internet]. 2010 Mar 1;59(3):325–332. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19091823
- Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol [Internet]. 1997 Dec;32(6):765–768. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9430014
- Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome. J Clin Gastroenterol [Internet]. 2013 Oct;48(6):1. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24100754
- Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2005 Nov 15;22(10):981–988. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16268973
- Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut [Internet]. 2007 Sep 5;56(9):1218–1225. [cited 2018 May 21]. DOI:10.1136/gut.2006.110858
- Hillsley K, Mccaul C, Aerssens J, et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil [Internet]. 2007 Sep;19(9):769–777. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17539892
- Mahmud A, Santha P, Paule CC, et al. Cannabinoid 1 receptor activation inhibits transient receptor potential vanilloid type 1 receptor-mediated cationic influx into rat cultured primary sensory neurons. Neuroscience [Internet]. 2009 Sep 15;162(4):1202–1211. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19463903
- Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med [Internet]. 2007 Jan 10;13(1):35–37. [2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17159985
- Fichna J, Sałaga M, Stuart J, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil [Internet]. 2014 Apr;26(4):470–481. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24460851
- Feng C-C, Yan X-J, Chen X, et al. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. Pain [Internet]. 2014 Aug;155(8):1591–1604. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24813296
- Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-hydroxytryptamine4–receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol [Internet]. 2015 Apr;13(4):701–708.e1. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25148765
- Van Diest SA, Stanisor OI, Boeckxstaens GE, et al. Relevance of mast cell–nerve interactions in intestinal nociception. Biochim Biophys Acta Mol Basis Dis [Internet]. 2012 Jan;1822(1):74–84. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21496484
- Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology [Internet]. 2004 Mar;126(3):693–702. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14988823
- Zhang L, Song J, Hou X. Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil [Internet]. 2016 Apr 30;22(2):181–192. [cited 2018 May 21]. DOI:10.5056/jnm15137
- Sałaga M, Kowalczuk A, Zielinska M, et al. Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2015 Oct;388(10):1069–1077. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26068703
- Mosińska P, Salaga M, Fichna J. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. Expert Opin Investig Drugs [Internet]. 2016 Mar 3;25(3):275–286. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26765585
- Deiana S, Gabbani T, Bagnoli S, et al. Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs [Internet]. 2015 Apr 3;20(2):247–261. [cited 2018 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25732091